Company news

Supernus Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

April 3, 2022

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

March 16, 2022

Supernus to Participate in Annual Cowen Health Care Conference

March 1, 2022

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

February 21, 2022

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

February 21, 2022

Supernus Pharmaceuticals Targeted in Ransomware Incident

November 23, 2021

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

November 23, 2021

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

November 22, 2021

Supernus to Participate in Annual Piper Sandler Healthcare Conference

November 17, 2021

Supernus to Participate in Upcoming November Investor Conferences

November 9, 2021

Supernus Announces Third Quarter 2021 Financial Results

November 2, 2021

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

October 26, 2021

Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

October 19, 2021

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

October 10, 2021

Supernus to Participate in Upcoming September Investor Conferences

September 1, 2021

Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

September 1, 2021

Supernus Announces Second Quarter 2021 Financial Results

August 3, 2021

Supernus to Host Second Quarter 2021 Financial Results Conference Call

July 21, 2021

Supernus to Present at Jefferies Virtual Healthcare Conference

May 24, 2021

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

May 23, 2021

Supernus Announces First Quarter 2021 Financial Results

May 4, 2021

Supernus Announces Paragraph IV ANDA Filing for XADAGO®

May 3, 2021

Supernus to Host First Quarter 2021 Financial Results Conference Call

April 26, 2021

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

April 1, 2021

Supernus to Present at Cowen Healthcare Conference

February 25, 2021

Supernus Announces Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call

February 22, 2021

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

February 21, 2021

Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients

February 7, 2021

Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

January 5, 2021

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

December 21, 2020

Supernus to Present at Two November Investor Conferences

November 10, 2020

Supernus Provides Regulatory Updates for SPN-812 and SPN-830

November 8, 2020

Supernus Announces Third Quarter 2020 Financial Results

November 2, 2020

Supernus to Host Third Quarter 2020 Financial Results Conference Call

October 26, 2020

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

October 4, 2020

Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments

September 13, 2020

Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

September 8, 2020

Supernus to Present at the Wells Fargo Virtual Health Care Conference

September 1, 2020

Supernus Announces Second Quarter 2020 Financial Results

August 17, 2020

Supernus Announces Preliminary Second Quarter 2020 Revenue

August 10, 2020

Supernus Sues Apotex for Infringement of Oxtellar XR® Patents

June 25, 2020

Supernus Completes Acquisition of CNS Portfolio from US WorldMeds

June 8, 2020

Supernus to Present at the Jefferies Virtual Health Care Conference

May 26, 2020

Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®

May 14, 2020

Supernus Announces First Quarter 2020 Financial Results

May 4, 2020

Supernus to Acquire CNS Portfolio from US WorldMeds

April 27, 2020

Supernus to Host First Quarter Results Earnings Conference Call

April 23, 2020

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

April 20, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.